
Tirzepatide Hub · FormBlends network
Get the tirzepatide dates, units and costs right, with the label behind every number.
For anyone on tirzepatide or thinking about it: when each dose step is allowed, how many units a vial dose is, what to do about a missed dose, and what it costs.
- 20 weeks
- label-minimum escalation from 2.5 mg to 15 mg
- The shortest the label allows to climb from the starting dose to the top dose.
- 96 hours
- missed-dose window; 72 hours to change injection day
- How long you have to take a missed dose before you skip it and wait for the next.
- $299 / $399 / $449
- LillyDirect vial self-pay tiers
- Lilly's own self-pay vial prices by dose, so you can compare any other offer.
Start here
Three ways in, depending on what you need right now
- 01Tirzepatide titration plannerLabel-minimum dates for every 2.5 mg step, from your start day to your prescribed maintenance dose.
- 02Mounjaro vs Zepbound: same molecule, two labelsMounjaro and Zepbound are the same drug, tirzepatide, sold under two names for different approved uses.
- 03Browse guides12 pages, most recently updated September 4, 2026
Interactive
Calculators
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
CalculatorTirzepatide titration planner
Label-minimum dates for every 2.5 mg step, from your start day to your prescribed maintenance dose.
CalculatorUnits to mg converter for tirzepatide vials
Insulin-syringe units for a prescribed mg dose at your vial's concentration, and back again.
CalculatorMissed dose and day-change helper
The 96-hour missed-dose window and the 72-hour day-change rule, applied to your times.
CalculatorSide-effect rates by dose
Label adverse reaction rates for your dose arm next to placebo, with the excess and where you are in escalation.
CalculatorTirzepatide self-pay cost tracker
Lilly's dated self-pay prices by strength, per injection, per mg and per year, with a first-year escalation total.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Compare
Mounjaro vs Zepbound: same molecule, two labels
You'll get: Mounjaro and Zepbound are the same drug, tirzepatide, sold under two names for different approved uses.
Where the Mounjaro and Zepbound labels agree (dosing, missed doses, strengths, storage) and where they differ (approved uses, dates, trials, side effects).

Compare
Tirzepatide vs semaglutide: what the head-to-head trial showed
You'll get: One trial compared the two drugs head to head for 72 weeks in 751 adults with obesity and no diabetes.
SURMOUNT-5 compared tirzepatide and semaglutide head to head for 72 weeks. The weight results, the main caveats, and how the doses and prices line up.

Costs
Zepbound self-pay prices: every Lilly price with its date
You'll get: Lilly's cash price for Zepbound vials is 299, 399 or 449 dollars for four weekly doses, depending on strength.
The list price at launch, the LillyDirect vial prices at each change since August 2024, the KwikPen self-pay tiers, and a cost tracker that turns them into cost per injection, per milligram and per year.

Guides
The tirzepatide titration schedule, step by step, with dates
You'll get: Titration, the step-up in dose, starts at 2.5 mg and rises by 2.5 mg after at least four weeks per step.
What the Zepbound and Mounjaro labels say about starting at 2.5 mg, moving up in 2.5 mg steps, and which doses count as maintenance. Plus a planner that turns the rules into calendar dates.

Guides
Missed a tirzepatide dose? The 96-hour rule and the 72-hour rule
You'll get: The label says a dose up to four days late can still be taken, and your usual day does not move.
Exactly what the Zepbound and Mounjaro labels say about a late dose, a skipped dose, and changing your injection day, with worked examples and a helper that applies the rules to your times.
Live updates
What changed since this site was written
Sources checked October 23, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching tirzepatide in the title (611 in total).
- Oral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide
OMICS · October 20, 2026 · PubMed 42902597
- Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice
Cardiol Rev · October 20, 2026 · PubMed 42897716
- Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Diabet Med · October 19, 2026 · PubMed 42897718
- Tirzepatide-Associated Lithium Toxicity: A Case Report
J Clin Psychopharmacol · October 19, 2026 · PubMed 42895194
- Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran
J Diabetes Metab Disord · October 17, 2026 · PubMed 42894545
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
17 pages across 3 sections, each sourced to a label, a trial or a dated manufacturer page.

Guides
You'll get: 12 sourced pages, each with a plain-English opener
What the Zepbound and Mounjaro labels say about starting at 2.5 mg, moving up in 2.5 mg steps, and which...

Compare
You'll get: 3 sourced pages, each with a plain-English opener
Where the Mounjaro and Zepbound labels agree (dosing, missed doses, strengths, storage) and where they...

Costs
You'll get: 2 sourced pages, each with a plain-English opener
The list price at launch, the LillyDirect vial prices at each change since August 2024, the KwikPen self-pay...
Why a whole site for one drug
Tirzepatide has two brand labels (Mounjaro for type 2 diabetes since May 13, 2022; Zepbound for weight reduction since November 8, 2023 and for obstructive sleep apnea since December 20, 2024), six strengths, four presentations, a 20-week label-minimum escalation, a 96-hour missed-dose window, a 72-hour day-change rule and a price list that Lilly has changed three times since August 2024. Each of those facts is small. Together they generate most of the questions people actually have. This site answers them one page at a time, with the label section or PubMed id next to every number.
What this site will not do
It will not tell you what dose to take or when to move up. The tools take the dose from your prescription and do arithmetic on dates, volumes and prices. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; where a page discusses it, that is said plainly. There are no reviews, testimonials, or star ratings here, and no clinician bylines. The byline is the FormBlends editorial team, which also runs formblends.com, a GLP-1 program with a commercial interest disclosed on every page.